- NCIt
- C132146
Loading cancer entity…
Loading cancer entity…
Clinical trials
900 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (101)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05108519 | Complications and Clinical Response in Cancer Patients Treated With Anti-VEGF-Related Therapies | recruiting | — | 170 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT05111561 | Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer | recruiting | Phase 1 | 42 | National Cancer Institute (NCI)NIH | 1 | Aug 10, 2026 |
| clinicaltrials |
| NCT03997370 | Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol | active not recruiting | Phase 1 | 350 | NRG OncologyOTHER | 2 | Aug 7, 2026 | clinicaltrials |
| NCT06630351 | Group Meaning-Centered Psychotherapy for the Improvement of Wellbeing in Caregivers of Patients With Serious Illness | enrolling by invitation | N/A | 80 | Mayo ClinicOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT07752953 | Personalized Neoantigen-pulsed Autologous Dendritic Cell Injections for Malignant Solid Tumors(ZSNeo-DC-RWS) | recruiting | N/A | 100 | ZSky Biotech IncINDUSTRY | 1 | Aug 7, 2026 | clinicaltrials |
| NCT01050504 | Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer | recruiting | — | 1,500 | University of WashingtonOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT04089358 | Mobile Health and Social Media Physical Activity Intervention Among Adolescent and Young Adult Childhood Cancer Survivors, the StepByStep Study | active not recruiting | Phase 3 | 387 | Children's Oncology GroupNETWORK | 2 | Aug 6, 2026 | clinicaltrials |
| NCT04090619 | Frequency of Cachexia in Ambulatory Cancer Patients and Psychological Burden in Patients and Their Primary Caregivers | active not recruiting | — | 192 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT06089408 | Weighted Blanket Use to Reduce Anxiety in Oncology Patients | recruiting | N/A | 114 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT07059884 | Distance-Based Exercise to Preserve Function and Prevent Disability(DEFEND) | recruiting | N/A | 104 | Alliance for Clinical Trials in OncologyOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT04083599 | GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 350 | GenmabINDUSTRY | 12 | Aug 4, 2026 | clinicaltrials |
| NCT05554341 | Testing the Use of Nilotinib and Paclitaxel as a Treatment for Patients With Prior Taxane Treatment, A ComboMATCH Treatment Trial | active not recruiting | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Aug 4, 2026 | clinicaltrials |
| NCT06880861 | Investigating Memory and Physical Activity After Cancer Treatment in Survivors of Adolescent and Young Adult Cancers(IMPACT) | recruiting | — | 150 | Mayo ClinicOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT01434316 | Veliparib and Dinaciclib in Treating Patients With Advanced Solid Tumors | active not recruiting | Phase 1 | 121 | National Cancer Institute (NCI)NIH | 1 | Aug 3, 2026 | clinicaltrials |
| NCT03878095 | Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors | active not recruiting | Phase 2 | 24 | National Cancer Institute (NCI)NIH | 1 | Aug 3, 2026 | clinicaltrials |
| NCT04320888 | Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial | active not recruiting | Phase 2 | 1 | National Cancer Institute (NCI)NIH | 3 | Aug 3, 2026 | clinicaltrials |
| NCT05687110 | Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes | recruiting | Phase 1 | 43 | National Cancer Institute (NCI)NIH | 2 | Aug 3, 2026 | clinicaltrials |
| NCT07741006 | Clinical Evaluation of [68Ga]Ga-ELI411 PET Imaging in Adult Patients With Solid Tumors | enrolling by invitation | Early Phase 1 | 18 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT02535312 | Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin | active not recruiting | Phase 1 / Phase 2 | 30 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT03030378 | Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors | active not recruiting | Phase 1 | 36 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT03284385 | Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2 | active not recruiting | Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT03872427 | Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study | active not recruiting | Phase 2 | 54 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT04491942 | Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer | active not recruiting | Phase 1 | 74 | National Cancer Institute (NCI)NIH | 2 | Jul 31, 2026 | clinicaltrials |
| NCT04616534 | Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors | active not recruiting | Phase 1 | 14 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT05372640 | Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors | recruiting | Phase 1 | 45 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT05691491 | Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness | recruiting | Phase 1 / Phase 2 | 42 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT07259304 | Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors | active not recruiting | — | 118 | University of Southern CaliforniaOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT07336238 | Group Retreat Psilocybin Therapy for the Treatment of Anxiety and Depression in Patients With Metastatic Solid Tumors or Incurable Hematologic Malignancies | active not recruiting | Phase 2 | 18 | University of WashingtonOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT03168737 | 18F-Fluoroazomycin Arabinoside PET-CT in Diagnosing Solid Tumors in Patients | active not recruiting | Phase 1 | 25 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT04439227 | Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I) | active not recruiting | Phase 2 | 33 | National Cancer Institute (NCI)NIH | 1 | Jul 30, 2026 | clinicaltrials |
| NCT04939090 | Olanzapine Versus Megestrol Acetate for the Treatment of Loss of Appetite Among Advanced Cancer Patients | active not recruiting | Phase 3 | 227 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT05039632 | Phase I/II Randomized Study of NBTXR3 Activated by Abscopal or RadScopal Radiation in Combination With Immunotherapy (Anti-PD-1/L-1) for Patients With Advanced Solid Malignancies | recruiting | Phase 1 / Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT06136897 | Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J) | active not recruiting | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Jul 30, 2026 | clinicaltrials |
| NCT02029001 | Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment(MOST plus) | recruiting | Phase 2 | 900 | Centre Leon BerardOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT05411523 | Assessing Effect of Spinal Cord Stimulation on Pain and Quality of Life With Chemotherapy-Induced Peripheral Neuropathy | recruiting | — | 20 | Mayo ClinicOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT06206863 | Community-Based Physical Activity Intervention for Underserved Cancer Survivors | recruiting | N/A | 200 | Roswell Park Cancer InstituteOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT06565260 | Community-Based Exercise and Nutrition Training and Education Program for Cancer Survivors | recruiting | N/A | 150 | Roswell Park Cancer InstituteOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT06569316 | Genetic Testing for the Prevention of Cancer in American Indian Communities (JUNIPER Trial) | recruiting | N/A | 300 | Mayo ClinicOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT07044336 | Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01) | recruiting | Phase 3 | 800 | AstraZenecaINDUSTRY | 28 | Jul 29, 2026 | clinicaltrials |
| NCT07723495 | Symptom Management to Improve Completion of Patient-reported Outcome Measures | not yet recruiting | N/A | 78 | Henry Ford Health SystemOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT07733141 | Mindfulness Intervention to Reduce Patient Reported Symptoms in Patients With Chronic Graft-Versus-Host Disease | not yet recruiting | N/A | 17 | City of Hope Medical CenterOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT05227326 | AOH1996 for the Treatment of Refractory Solid Tumors | recruiting | Phase 1 | 92 | City of Hope Medical CenterOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT06161025 | A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | recruiting | Phase 2 / Phase 3 | 860 | Daiichi SankyoINDUSTRY | 19 | Jul 28, 2026 | clinicaltrials |
| NCT03155620 | Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) | active not recruiting | Phase 2 | 1,377 | National Cancer Institute (NCI)NIH | 4 | Jul 24, 2026 | clinicaltrials |
| NCT07724756 | Phase II Study of QLC2519 in Pediatric Solid Tumor Participants | recruiting | Phase 2 | 18 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 24, 2026 | clinicaltrials |
| NCT03917043 | APG-2449 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 165 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Jul 23, 2026 | clinicaltrials |
| NCT06942104 | Imaging of Solid Tumors Using 18F-TRX | recruiting | Phase 1 | 56 | Rahul AggarwalOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT07606287 | Studying the Workflow of the American College of Surgeons Geriatric Surgery Program to Improve Clinical Outcomes in Older Adults Undergoing Surgery at the James Cancer Hospital | not yet recruiting | N/A | 4,000 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT02298959 | Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer | active not recruiting | Phase 1 | 59 | National Cancer Institute (NCI)NIH | 2 | Jul 22, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Aug 10, 2026source: clinicaltrials